Endpoints News 16. Dez. 2025 Nektar's immunology drug misses in Phase 2b, execs cite enrollment errors
Endpoints News 16. Dez. 2025 J&J backs financing round for Stanford CAR-T cell therapy spinout Link Cell
Endpoints News 16. Dez. 2025 OrsoBio obesity data; Monte Rosa's prostate cancer pill; Development pacts for Adaptive and SandboxAQ
Endpoints News 16. Dez. 2025 Chronic pain biotech Ambros Therapeutics emerges with $125M and Vivek Ramaswamy on board
Endpoints News 16. Dez. 2025 Aeovian gets $55M for tuberous sclerosis complex, to explore prospects in obesity
Endpoints News 15. Dez. 2025 FDA wants to use more real-world data and calls again for early-phase trials reform
Endpoints News 15. Dez. 2025 Enhertu combo wins FDA approval for first-line use in metastatic breast cancer
Endpoints News 15. Dez. 2025 FDA speeds up review of J&J's multiple myeloma combo treatment following positive data
Endpoints News 15. Dez. 2025 With GLP-1 microdoses, Noom targets lower-BMI group outside FDA obesity drug labels
Endpoints News 15. Dez. 2025 Aviceda's geographic atrophy drug fails mid-stage study. Can it do better in Phase 3?
Endpoints News 15. Dez. 2025 Areteia Therapeutics to wind down after terminating Phase 3 asthma studies